HomeCompareYIPCF vs ABBV

YIPCF vs ABBV: Dividend Comparison 2026

YIPCF yields 7.02% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $78.7K in total portfolio value
10 years
YIPCF
YIPCF
● Live price
7.02%
Share price
$0.29
Annual div
$0.02
5Y div CAGR
-21.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$23.6K
Annual income
$77.62
Full YIPCF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — YIPCF vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodYIPCFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, YIPCF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
YIPCF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

YIPCF
Annual income on $10K today (after 15% tax)
$596.49/yr
After 10yr DRIP, annual income (after tax)
$65.98/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABBV beats the other by $20,990.03/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of YIPCF + ABBV for your $10,000?

YIPCF: 50%ABBV: 50%
100% ABBV50/50100% YIPCF
Portfolio after 10yr
$63.0K
Annual income
$12,424.69/yr
Blended yield
19.72%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

YIPCF
No analyst data
Altman Z
1.3
Piotroski
7/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

YIPCF buys
0
ABBV buys
7
PoliticianChamberTickerTypeAmountDate
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-18
Julia Letlow🏢 House$ABBV▼ Sell$1,001 - $15,0002025-12-08
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-11-13
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-31
Lisa McClain🏢 House$ABBV▼ Sell$1,001 - $15,0002025-10-30
Lisa McClain🏢 House$ABBV▲ Buy$1,001 - $15,0002025-10-30
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-22
Julie Johnson🏢 House$ABBV▼ Sell$1,001 - $15,0002025-08-14
John Boozman🏛 Senate$ABBV▼ Sell$1,001 - $15,0002025-08-11
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricYIPCFABBV
Forward yield7.02%3.06%
Annual dividend / share$0.02$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-21.2%40.6%
Portfolio after 10y$23.6K$102.3K
Annual income after 10y$77.62$24,771.77
Total dividends collected$2.6K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: YIPCF vs ABBV ($10,000, DRIP)

YearYIPCF PortfolioYIPCF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$11,253$552.98$11,550$430.00$297.00ABBV
2$12,499$458.27$13,472$627.96$973.00ABBV
3$13,749$374.86$15,906$926.08$2.2KABBV
4$15,015$303.67$19,071$1,382.55$4.1KABBV
5$16,310$244.23$23,302$2,095.81$7.0KABBV
6$17,647$195.38$29,150$3,237.93$11.5KABBV
7$19,038$155.68$37,536$5,121.41$18.5KABBV
8$20,495$123.69$50,079$8,338.38$29.6KABBV
9$22,027$98.06$69,753$14,065.80$47.7KABBV
10$23,647$77.62$102,337$24,771.77$78.7KABBV

YIPCF vs ABBV: Complete Analysis 2026

YIPCFStock

Yip's Chemical Holdings Limited, an investment holding company, produces and sells petrochemical products in the People's Republic of China, Hong Kong, and internationally. It operates through Solvents, Coatings, Inks, Lubricants, and Properties segments. The Solvents segment produces industrial organic solvents, such as ethyl acetate, normal butyl acetate, mixed butyl acetate, ethanol, and butyl acrylate used in coatings, tannery, medicine, and adhesives industries. The Coatings segment provides architectural coatings, including inner and outer wall paints, and water-based emulsion and wood paints for the household paints market; industrial coatings comprising coatings for furniture, and plastic and mechanical products; and alkyd, acrylic, UV, amino, and water-based resins, as well as PU hardeners. This segment offers its products under the Camel, Aquapro, and VIVA brands. The Inks segment provides plastic and paper printing inks for use in food, drinks and gift packaging, and paper printing applications. The Lubricants segment offers automotive and industrial lubricants, including engine oils, antifreezes, system coolants, brake fluids, greases, gear oils, automatic transmission fluids, hydraulic oils, turbine oils, heat conducting oils, slideway oils, compressor oils, and circulating oils under the Hercules brand. It also provides specialty lubricants under the Pacoil brand to the metal processing, automobiles, home appliances, electronics, steel, toys, power generation, cement, textiles, foundry, plastics, chemicals, paper making, glass, wires, and cables industries. The Properties segment invests in properties. The company also trades in coatings, solvents, resins, inks, lubricants, and sanitizing products; offers treasury and car maintenance services; and generates and sells electricity. The company was formerly known as Hang Cheung Hong. Yip's Chemical Holdings Limited was founded in 1971 and is headquartered in Wanchai, Hong Kong.

Full YIPCF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this YIPCF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

YIPCF vs SCHDYIPCF vs JEPIYIPCF vs OYIPCF vs KOYIPCF vs MAINYIPCF vs JNJYIPCF vs MRKYIPCF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.